1 **Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies** 2 **unique epitopes with potential for diagnostic test development**

3
4 Pavlo Holenya^{1*}, Paul Joris Lange^{2,3,5,7*}, Ulf Reimer¹, Wolfram Woltersdorf³, Thomas Pan-
5 terodt³, Michael Glas³, Mark Wasner³, Maren Eckey¹, Michael Drosch¹, Jörg-Michael Hol-
6 lidt^{2,4}, Michael Naumann⁵, Florian Kern^{1,6}, Holger Wenschuh¹, Robert Lange^{2,3}, Karsten
7 Schnatbaum^{1,*}, Frank F. Bier^{2,7,*}

8
9 ¹ JPT Peptide Technologies GmbH, Berlin, Germany

10 ² Institute for Molecular Diagnostics and Bioanalysis - IMDB gGmbH, Hennigsdorf, Ger-
11 many

12 ³ KH Labor GmbH, Bernburg, Germany

13 ⁴ in.vent GmbH, Hennigsdorf, Germany

14 ⁵ Institute of Experimental Internal Medicine, Medical Faculty, Otto von Guericke Univer-
15 sity, Magdeburg, Germany

16 ⁶ Brighton and Sussex Medical School, Department of Clinical and Experimental Medicine,
17 Brighton, UK

18 ⁷ University of Potsdam, Institute for Biochemistry and Biology, Potsdam, Germany

19 *corresponding authors

20
21 Joint first authors*, „The authors wish it to be known that, in their opinion, the first 2 au-
22 thors should be regarded as joint First Authors“

23
24
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Summary**

26
27 Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-
28 2 is not fully understood yet but may be a crucial factor of immune protection. The possibil-
29 ity of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses
30 (HCoVs) would have important implications for immune protection but also for the develop-
31 ment of specific diagnostic ELISA tests. Using peptide microarrays, n=24 patient samples
32 and n=12 control samples were screened for antibodies against the entire SARS-CoV-2
33 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a
34 (AP3A) of the HCoV strains SARS, MERS, OC43 and 229E. While widespread cross-reac-
35 tivity was revealed across several immunodominant regions of S and N, IgG binding to
36 several SARS-CoV-2-derived peptides provided statistically significant discrimination be-
37 tween COVID-19 patients and controls. Selected target peptides may serve as capture
38 antigens for future, highly COVID-19-specific diagnostic antibody tests.

39
40 Keywords: COVID-19, SARS-CoV-2, immunity, peptide scan, epitope mapping, peptide
41 microarray, diagnostics, epitope score, cross reactivity.

42
43

44

45 Introduction

46

47 The COVID-19 pandemic hit the world unprepared. At the time of writing global cases
48 were in the millions and still rising [WHO, 2020]. Apart from social distancing, rapid testing
49 of suspected cases and contacts is the key measure helping to contain the infection. The
50 experience from many countries has shown that imprecise or incomplete knowledge of in-
51 fection prevalence and viral transmission rates may result in a wrong assessment of the
52 epidemiological situation, wrong predictions, and inadequate guidance and action with po-
53 tentially grave consequences for societies and national economies. These observations
54 underline the global need for reliable and highly specific tests.

55 SARS-CoV-2 infection is generally confirmed by RT-PCR on swabs taken from the nose
56 and throat, however, virus load quickly becomes unmeasurable following the acute infec-
57 tion. Reliable serological monitoring will therefore be instrumental in determining the
58 SARS-CoV-2 infection status of larger populations, determine existing immunity, and track
59 local outbreaks [Pollán et al., 2020]. In the near future it may also greatly contribute to as-
60 sessing vaccine-induced immunity at the population level. However, SARS-CoV-2 anti-
61 body testing is much more complex than appears at first glance. Currently available anti-
62 body tests are not very specific and may produce conflicting results [Krammer and Simon,
63 2020; Lisboa Bastos et al., 2020; Bond et al., 2020]. A plausible reason for that might be
64 that antibody tests have generally been validated by samples from clinically symptomatic
65 rather than mild or even asymptomatic cases. However, the reason for the overall unreli-
66 able performance of antibody tests is not fully understood. Interestingly, it has been sug-
67 gested that, particularly in mild and asymptomatic cases, IgG responses may not be de-
68 tectable until 3-4 weeks after infection [Fafi-Kremer et al., 2020] which may compound the
69 issue.-

70 A large number of studies have examined antibody responses to SARS-CoV-2 [Siracu-
71 sano et al., 2020]. Most of these used full-length proteins as capture antigens and thus
72 have not identified reactivity at the single epitope level. Only few references [Amrun et al.,
73 2020; Farrera-Soler et al. 2020; Poh et al., 2020; Wang et al., 2020; Zhang1 et al., 2020]
74 including preprints [Zhang2 et al., 2020; Smith et al., 2020; Dahlke et al., 2020; Ladner et
75 al., 2020] provide more detailed information on antibody specificity. Most of these studies
76 comprise small sample numbers ($n \leq 10$) and only one of them [Ladner et al., 2020] exam-
77 ined cross-reactivity with other HCoVs despite *in silico* analysis indicating that significant
78 cross-reactivity is to be expected [Ahmed et al., 2020; Grifoni et al., 2020].

5

6

79 Here we present a first study of the humoral immune response against SARS-CoV-2 at the
80 single linear peptide epitope level covering all SARS-CoV-2 antigens as well as the S, N, E
81 and M proteins of the pandemic/epidemic-related human Severe Adult Respiratory Syn-
82 drome and Middle East Respiratory Syndrome-related human coronaviruses (SARS-CoV
83 and MERS-CoV), and, in addition, the seasonal cold-related strains human coronavirus
84 OC43 and 229E. Our results provide deeper insight into the immune response to HCoVs
85 than previously published work which could pave the way to SARS-CoV-2 specific and reli-
86 able COVID-19 diagnostic test development.

87

88

89

90 **Results**

91

92 **Identification of immunodominant epitopes**

93 Serum samples from COVID-19 patients analyzed by peptide microarray technology ex-
94 hibited high levels of antibody reactivity, whereas almost no reactivity was detected with
95 control samples. Several immunodominant regions were identified. These were located
96 primarily on the SARS2 S and N proteins (**Figure 1, Supplementary Figures 1-6**). There
97 was also strong IgG reactivity to several peptides derived from the SARS2 M, AP3A and
98 R1AB proteins, however, immune dominance was less pronounced in these proteins
99 (**Supplementary Figures 3, 5 and 6**). All remaining SARS2 antigens demonstrated no or
100 only minor immunogenicity in terms of IgG response.

101 For quantitative characterization of the identified immunodominant regions, responses in
102 SARS-CoV-2 infected individuals were compared to those in the control group for each
103 single peptide and for combinations of three, four and five peptides by the non-parametric
104 Wilcoxon Rank Sum test. Results for selected peptide hits and the best combinations
105 thereof are presented in **Figure 2. Table 1** shows a selection of identified epitopes repre-
106 sented either by single peptides or by common core sequences derived from two or more
107 overlapping peptides. To narrow down the identified immunodominant peptides to the po-
108 tential immunodominant epitope sequences, the peptides with the highest accuracy scores
109 (calculated as the sum of true positive and true negative divided by the total number of ob-
110 servations) were listed in the order of appearance in the corresponding antigens. If appli-
111 cable, sequence overlaps were marked in red. A complete list of peptides showing the
112 most significant discrimination between SARS-CoV-2 infected and the control group can
113 be found in **Supplementary Table 2**.

114

115 **Microarray assay results strongly correlate with a commonly used diagnostic test**

116 To evaluate the diagnostic potential of a peptide-based assay, a comparison with a com-
117 monly used diagnostic test utilizing a full-length viral antigen was performed. **Figure 3**
118 shows the quantitative results obtained for the SARS-CoV-2 infected group with a) the
119 commercial ELISA test (EUROIMMUN) and b) the peptide microarray. Both assays
120 demonstrated a strong correlation with a Spearman's rank correlation coefficient of 0.88.

121

122 **Cross-reactivity with seasonal common cold coronaviruses experimentally con-** 123 **firmed**

9

10

Antibody cross-reactivity between SARS-CoV-2 and seasonal common cold coronaviruses may be highly important with respect to the clinical course of COVID-19 and at the same time represents a challenge for the development of a specific test. We, therefore, analyzed IgG reactivity to peptides derived from the S, N, E, and M proteins of SARS-CoV, MERS-CoV, HCoV-OC43 and HCoV-229E (**Supplementary Table 1**) in both groups. This revealed highly similar IgG binding profiles against the N and M proteins of SARS-CoV-2 and SARS-CoV, whereas the corresponding proteins of the remaining viral strains showed only weak and scattered signals (**Supplementary Figures 1 and 3**). Most notably, peptides derived from the S protein of all viral strains showed clear signal patterns among SARS-CoV-2 positive patient samples, suggesting that this antigen contained cross-reactive determinants (**Supplementary Figure 2**). IgG reactivity was directed at two sequence regions in particular (**Figure 4**). Each of these regions was represented by overlapping peptides containing highly conserved cross-reactive epitopes (**Figure 4, right panel**). One consensus motif, **R₀₈₁₅-S-IED-LF₀₈₂₃** (numbers referring to the location of the epitope in the SARS2 antigen) was present in all five viruses, and a second consensus motif, **F₁₁₄₈--ELD--FKN₁₁₅₈** was found in the viruses SARS-CoV-2, SARS-CoV, MERS-Cov and HCoV-OC43, but not HCoV-229E.

To further analyze serologic cross-reactivity of SARS-CoV-2 positive patients against common cold coronaviruses we performed a gapless alignment of the N and S sequences from all coronaviruses (**Figure 5**). For each strain, this yielded the sequence regions that were complementary to the previously identified SARS-CoV-2 epitopes. Finally, for each of the amino acid residues of the thus identified sequences, the median signal of all overlapping peptides containing that residue was calculated and visualized by the same colour coding as in the previously presented heatmaps (**Figure 5**). The immunodominant epitopes #6 and #7 of the N protein and #1 and #3 of the S protein of SARS-CoV-2 (see **Table 1** for a list of the sequences) displayed strong signals with samples from SARS-CoV-2 infected individuals compared to the control samples. At the same time, no signals were found for the homologous sequences of the other coronavirus strains, indicating that IgG responses to these epitopes may be truly specific for SARS-CoV-2 (**Figure 5, Top**). SARS-CoV-2 epitopes #1-#5 of the N and #2 and #6 of the S protein showed a strong homology to SARS-CoV which resulted in serologic cross-reactivity to this virus (**Figure 5, Middle**). Finally, epitopes #4 and #5 of the S protein were the least SARS-CoV-2 specific and exhibited considerable cross-reactivity between all sequence variants (**Figure 5, Bottom**).

Discussion

The work presented here used a systematic approach that provides deeper insight into the humoral immune response to HCoV and lays a fundament for the development of specific serological tests of SARS-CoV-2 infection. The approach is based on four pillars: (i) peptide microarray based analysis of the humoral immune response against the entire SARS-CoV-2 proteome and other HCoV proteomes, (ii) identification of all immunodominant epitopes at high resolution, (iii) selection of SARS-CoV-2 peptides that are recognized by serum antibodies of COVID-19 patients but not by serum antibodies from controls and (iv) selection of SARS-CoV-2 peptides whose homologous peptides in other HCoVs are not recognized by serum antibodies from COVID-19 patients.

Our analysis of IgG responses of COVID-19 patients against all peptides of the SARS-CoV-2 proteome revealed that IgG binding was mainly focused on both the S and N proteins, indicating that these two proteins are indeed immunodominant (**Figure 1, Supplementary Figures 1-6**). The fact that the M, AP3A and R1ab proteins were also recognized, however, shows that responses are not exclusive to S and N. It remains to be resolved in future studies if the most dominant immune responses against certain antigens are also the most effective responses concerning disease protection.

Applying stringent bioinformatic criteria we identified several linear epitopes that were immunodominant among SARS-CoV-2 positive patients (**Table 1**). Previous analyses of antibody epitopes in SARS-CoV revealed that many such epitopes were indeed linear [Guo et al., 2004; Shichijo et al., 2004]. Interestingly, some immunodominant regions in the N and S proteins that have been previously reported in the literature [Poh et al., 2020; Amrun et al., 2020] correspond closely to epitopes #3 from N and #1 and #4 from S (**Table 1**), respectively. This confirms our findings and illustrates the potential of the peptide microarrays for epitope identification. Longer sequence stretches encompassing some of the epitopes identified here have also been described in published manuscripts [Wang et al., 2020; Farrera-Soler et al., 2020; Zhang1 et al., 2020] or in non-peer-reviewed preprint publications, however, without narrowing them down [Zhang2 et al., 2020; Smith et al., 2020; Dahlke et al., 2020]. With our comprehensive peptide library we further completed the list of the previously described immunodominant SARS-CoV-2 regions and specified the corresponding epitopes.

192 The most important question with respect to developing a reliable diagnostic test was,
193 however, whether the IgG response to the identified SARS2-specific peptides can effec-
194 tively distinguish COVID-19 patients and controls. This was indeed the case, as a compari-
195 son of serum reactivity in COVID-19 patients versus the control group, peptide by peptide,
196 identified many peptides to which responses were significantly different between the
197 groups (**Table 1, Figure 2A**). The combination of selected peptides derived from different
198 SARS-CoV-2 antigens further improved the discrimination between the sample groups as
199 shown in **Figure 2B**, and also might increase sensitivity when applied in a diagnostic test.
200 As a further step to assess the diagnostic potential of the obtained data, the quantitative
201 results obtained with the peptide microarrays were compared with those generated by a
202 commercial ELISA test (**Figure 3**). We observed a very strong correlation what suggests
203 that a combination of short linear synthetic peptides may be used for the development of a
204 diagnostic test instead of full-length antigens. Moreover, as it was found that only a small
205 proportion of all peptides forms B cell epitopes, the selection of peptides must not neces-
206 sarily span the whole antigen, but might be limited to immunodominant regions identified
207 by a peptide microarray screening.

208
209 Multiple studies utilizing *in silico* prediction of SARS-CoV-2 immunogenicity [Wang et al.,
210 2020; Yuan et al., 2020; Palm et al., 2020; Smith et al., 2020] postulated the existence of
211 cross-reactive immunity between different coronaviruses, in particular between SARS-
212 CoV-2 and SARS-CoV, because several known B-cell and T-cell target peptides in SARS-
213 CoV exist almost identically in SARS-CoV-2. Cross-reactive T cell epitopes were experi-
214 mentally confirmed by several authors [Braun et al., 2020; Mateus et al., 2020] and some
215 degree of B cell cross reactivity to HCoV-229E has been identified by western blot analysis of
216 full length antigens [Bonifacius et al., 2020]. However, there is still a lack of experimental
217 data identifying cross-reactive B cell epitopes. We found two immunodominant regions in
218 the SARS-CoV-2 S protein (1148-FKEELDKYFKN-1158 and 0815-RSFIEDLLF-0823)
219 which were highly cross-reactive with the prevalent seasonal "common cold" coron-
220 aviruses HCoV-OC43 and HCoV-229E (**Figure 4**). A similar result obtained with a different
221 assay based on 30-mer peptide cDNA-fusion pools in a non-peer review publication con-
222 firms our findings [Ladner et al., 2020].

223 The identified cross-reactivity is of particular interest, as it suggests that exposure to com-
224 mon cold HCoV-229E may provide a degree of immunity to SARS-CoV-2. The presence of
225 such preexisting immunity may have a positive impact on the course and outcome of
226 COVID-19. Arguments against this hypothesis are, however, that it has been reported that

the common cold coronaviruses generate only a weak and transient humoral immune response [Huang et al., 2020] and that reconvalescents from SARS1 – a virus that is structurally more closely related to SARS2 than the common cold coronaviruses – did not have SARS2 neutralization titers in plasma [Lv et al., 2020]. Of note, preexisting immunity could also be detrimental, as it may inhibit production of antibodies with certain specificity, *i.e.* a phenomenon called original antigenic sin. This phenomenon may be responsible for ineffective vaccine response to a recently developed Cytomegalovirus vaccine [Baraniak et al., 2019]. Even worse, existing antibodies could promote infection of target cells by facilitating viral uptake, a phenomenon called antibody-dependent enhancement [Fierz et al., 2020; Arvin et al., 2020]. Our results demonstrate that some of the patient sera, *e.g.* numbers SARS_20 to SARS_23, show stronger reactivity towards the HCoV-OC43 variant of the cross-reactive epitope II than to the respective SARS-CoV-2 epitope (**Figure 4**). This is an interesting observation as there is no other logical explanation for this than that the antibody was made in response to the HCoV-OC43 virus in a previous HCoV-OC43 infection. A number of additional peptides that led to strong IgG responses (**Figure 4**) support the notion of preexisting B cell immunity to SARS-CoV-2 in those exposed to other coronaviruses. It will be up to future studies with larger cohorts to determine whether preexisting immunity has an effect on disease severity.

While the physiological effects of serologic cross-reactivity require further studies, it is obvious that it makes the development of reliable antibody tests more difficult. Antibody based ELISA tests that use full-length conformational antigens or parts thereof as capture antigens might give false positive results in individuals with previous exposure to common cold coronaviruses. In this regard, the usage of the S protein antigen in a diagnostic test might be particularly problematic due to several known homologous regions between SARS-CoV-2 and other coronaviruses. The detailed analysis of IgG reactivity against SARS-CoV, MERS-CoV, HCoV-OC43 and HCoV-229E S and N proteins indeed revealed widespread cross-reactivity in several immunodominant regions (**Figure 4**), which is most probably a consequence of sequence homology. However, the observed cross-reactivity could not be predicted by simple sequence alignment unless 100% homology was present. With a view to develop a diagnostic test, our finding that epitopes #6 and #7 of N and #1 and #3 of S appear to provide a high specificity for SARS-CoV-2 (**Figure 5**) is of major interest. A combination of such epitopes in a peptide ELISA may increase sensitivity without increasing the risk of false positives.

262 In conclusion, our study experimentally confirms antibody cross-reactivity between SARS-
263 CoV-2 and other HCoVs, but at the same time reveals antibody reactivity to several epi-
264 topes that are unique to SARS-CoV-2. These epitopes are of particular interest for the de-
265 velopment of diagnostic tests. Additional, larger studies are required to confirm these re-
266 sults and accelerate the development of a sensitive and specific test for SARS-CoV-2 in-
267 fection that we urgently need in order to deal with the current and possible future waves of
268 this pandemic.
269
270

271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288

Acknowledgements

The authors are grateful for the assistance of the following local health authorities (Gesundheitsämter) of Landkreis Börde (Frau Dr. Kontzog and Team), Landkreis Salz-landkreis (Frau Leonhardt and Team), and Landkreis Harz (Frau Dr. Christiansen and Team) for their support in identifying appropriate blood donors.

Author Contributions

W.W., T.P., M.G., M.W. collected samples; P.H., P.J.L. conducted the experiments; P.H., P.J.L.; U.R. performed data analysis; M.N., R.L., F.B. initiated and projected the study; P.H., U.R., M.E., M.D., J.M.H, M.N., F.K., H.W., R.L, K.S., F.B. designed the experiments; P.H., P.J.L., F.K., R.L., K.S., F.B. wrote the paper.

Declaration of Interests

P.H., U.R., M.E., M.D., F.K., H.W. and K.S. are employees of JPT Peptide Technologies GmbH which commercialized the peptide microarrays use in this study.

289

290 **Figure 1. Peptide microarray based analysis of IgG responses to SARS-CoV-2 Nucleopro-**
 291 **tein (N) and Spike glycoprotein (S) measured in human sera.** Heatmaps represent two groups
 292 of serum samples: SARS-CoV-2 infected and control groups. The two upper rows of the heatmaps
 293 reflect signals obtained with detection antibody only (no serum). Columns represent peptide se-
 294 quences, rows represent samples. Colours indicate the signal values obtained from triplicate spots
 295 ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of
 296 65535 light units). The two upper rows of the heatmaps reflect signals obtained with detection anti-
 297 body only (no serum). The right column in each heatmap reflects the highest possible signal inten-
 298 sity. Box plots show the signal distribution in each group for selected immunodominant regions.

299

300 **Figure 2. Selected single peptides and combination of peptides providing the best discrimi-**
 301 **nation between sample groups.** A. For each peptide the signal intensity was compared between
 302 the SARS-CoV2 infected ("SARS2") and the control (CTRL) group by Wilcoxon Rank Sum test with
 303 the box plots showing the ability of selected peptides to discriminate between groups. B. Combina-
 304 tions of three, four and five peptides providing the best discrimination between the groups by
 305 Wilcoxon Rank Sum test. Each data point represents the sum of the signals of the combined pep-
 306 tides.

307

308 **Figure 3. Correlation between the commercial ELISA and the peptide microarray signals.**
 309 The Spearman's correlation coefficient between the ELISA signal and the summed microarray sig-
 310 nals for SARS-CoV-2 S and N peptides was calculated for sera from SARS-CoV-2 infected pa-
 311 tients. In the ELISA assay, which used a recombinant S glycoprotein as capture antigen, the quo-
 312 tient of the extinction of the patient sample in comparison to the calibrator was used as net assay
 313 signal. The total microarray signals for each sample were calculated as a sum of all corresponding
 314 signal intensities above the upper 10^{-160} quantile of the noise distribution.

315

316 **Figure 4. Serologic cross-reactivity between SARS-CoV-2 and other Coronaviruses.** Left:
 317 Conserved S protein regions of different coronaviruses showing a strong IgG seroreactivity in sera
 318 from SARS-CoV-2 infected patients. Each region is represented by two overlapping peptides
 319 (framed red). Right: cross-reactive motifs resulting from sequence alignment of the peptides re-
 320 flecting a high homology. Motif II was present in all five viruses, whereas motif I was found in the
 321 viruses SARS-CoV-2, SARS-CoV, MERS-Cov and HCoV-OC43, but not HCoV-229E.

322

23
24

323 **Figure 5. Potential Nucleoprotein (N) and Spike glycoprotein (S) epitope combinations for a**
324 **diagnostic test.** Each epitope (depicted with the same numbering as in Figure 2) is represented
325 by a heatmap showing aligned sequences of the investigated coronaviruses. Blue frames indicate
326 the inferred epitope length. The colored background of each amino acid residue reflects the me-
327 dian signal intensity of the SARS-CoV-2 positive cohort calculated from signals of all peptides on
328 the microarray which contained this residue. The color code ranges from white (0 or low intensity)
329 over yellow (middle intensity) to red (maximal intensity of 65535 light units). Per cent sequence ho-
330 mology to SARS-CoV-2 is indicated in green. Based on the observed cross-reactivity of the SARS-
331 CoV-2-induced IgG responses toward the other virus types, certain combinations of SARS-CoV-2
332 epitopes may be used to develop diagnostic tests with different specificities.

333

Table 1. Selected immunodominant SARS-CoV-2 epitopes identified by peptide microarrays.
Selected peptides providing good separation between the groups are listed. Immunodominant epitopes (highlighted red) are derived from the sequences of (overlapping) peptides.

Peptide	Sequence	Ratio Median SARS2/ CTRL	P value	AUC	Immunodominant epitope	#
AP3A_0253-0267	SGVVNPVMEPIYDEP	1.8	1.2E-02	0.76	0261 - EPIYDEP - 0267	1
AP3A_0257-0271	NPVMEPIYDEPTTTT	1.9	5.6E-03	0.78		
AP3A_0261-0275	EPIYDEPTTTTSVPL	3.0	5.0E-03	0.78		
NCAP_0009-0023	QRNAPRITFGGSPDS	2.1	6.1E-04	0.84	0013 - PRITFGGSPDS - 0023	1
NCAP_0013-0027	PRITFGGSPDSTGSN	2.6	1.6E-03	0.82		
NCAP_0033-0047	SGARSKQRRPQGLPN	2.7	7.3E-03	0.78	0037 - SKQRRPQGLPN - 0047	2
NCAP_0037-0051	SKQRRPQGLPNTAS	4.6	4.0E-03	0.79		
NCAP_0157-0171	IVLQLPQGTTLPKGF	7.1	5.6E-03	0.78	0161 - LPQGTTLPKGF - 0171	3
NCAP_0161-0175	LPQGTTLPKGFYAEG	5.0	8.4E-02	0.68		
NCAP_0217-0231	AALALLLLDRLNQLE	2.7	8.1E-04	0.83	0221 - LLLLDRLNQLE - 0231	4
NCAP_0221-0235	LLLLDRLNQLESKMS	12.7	4.3E-07	0.96		
NCAP_0357-0371	IDAYKTFPPTPEPKD	3.2	1.7E-04	0.87	0357 - IDAYKTFPPTPEPKD - 0371	5
NCAP_0373-0387	KKKADETQALPQRQK	3.1	2.1E-03	0.81	0377 - DETQALPQRQK - 0387	6
NCAP_0377-0391	DETQALPQRQKKQT	6.1	5.7E-05	0.89		
NCAP_0385-0399	RQKKQQTVTLLPAAD	6.1	3.8E-04	0.85	0393 - TLLPAADLDDFSKQL - 0407	7
NCAP_0389-0403	QQTVTLLPAADLDDF	5.6	1.1E-03	0.83		
NCAP_0393-0407	TLLPAADLDDFSKQL	39.4	1.7E-05	0.91		
NCAP_0397-0411	AADLDDFSKQLQQSM	30.9	5.3E-06	0.93		
SPIKE_0553-0567	TESNKKFLPFQQFGR	3.4	5.2E-04	0.84	0557 - KKFLPFQQFGR - 0567	1
SPIKE_0557-0571	KKFLPFQQFGRDIAD	5.1	9.9E-05	0.88		
SPIKE_0657-0671	NNSYECDIPIGAGIC	1.6	2.6E-02	0.73	0661 - ECDIPIGAGIC - 0671	2
SPIKE_0661-0675	ECDIPIGAGICASYQ	1.8	1.9E-02	0.74		
SPIKE_0785-0799	VKQIYKTPPIKDFGG	2.8	1.1E-06	0.95	0789 - YKTPPIKDFGG - 0799	3
SPIKE_0789-0803	YKTPPIKDFGGFNFS	4.8	4.5E-04	0.85		
SPIKE_0809-0823	PSKPSKRSFIEDLLF	5.5	1.6E-03	0.82	0813 - SKRSFIEDLLF - 0823	4
SPIKE_0813-0827	SKRSFIEDLLFNKVT	3.0	1.2E-02	0.76		
SPIKE_1145-1159	LDSFKEELDKYFKNH	11.2	1.1E-04	0.88	1145 - LDSFKEELDKYFKNH - 1159	5
SPIKE_1253-1267	CCKFDEDDSEPVKLG	2.8	6.3E-03	0.78	1259 - DDSEPVKLGVKLH - 1271	6
SPIKE_1257-1271	DEDDSEPVKLGVKLH	3.3	4.7E-05	0.89		
SPIKE_1259-1273	DDSEPVKLGVKLHYT	3.1	1.7E-05	0.91		
VME1_0005-0019	NGTITVEELKKLLEQ	6.3	8.1E-04	0.83	0005 - NGTITVEELKKLLEQ - 0019	1
R1AB_1657-1671	KYPQVNGLTSLKWAD	1.7	2.6E-02	0.73	1657 - KYPQVNGLTSLKWAD - 1671	1
R1AB_2153-2167	TTNIVTRCLNRVCTN	1.6	1.9E-02	0.74	0005 - TTNIVTRCLNRVCTN - 0019	2

342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
29
30

METHOD DETAILS

Blood sampling. Following written informed consent peripheral blood samples were obtained by vene puncture / from periperal venous catheters. Multiple samples were collected into a Vacutainer Tube (Serum-separating tube) with a volume of 8 ml. Serum was collected after centrifugation, samples were allowed to clot for 1 hour, and the clot was removed by centrifugation. The samples were divided and stored in aliquots at -80°C until use.

RT-PCR RNA collection according to Guidelines of the CDC. Samples were collected from the upper respiratory tract using a nasopharyngeal (NP) with plastic by trained medical staff. In the case of the NP the swab was inserted deeply into the nostril until resistance was encountered and the depth was equal to the distance from the nose to the ears of the patients. The swab was gently rubbed against the nasopharynx and left there in order to absorb enough secret. Swabs were then immediately placed into a sterile transport tube. Samples were cooled and tested no more than 48 hours after collection.

Participants.

Controls: Controls consist of excess serum samples collected in accordance to the regulations for the use of rest samples for scientific purposes at the KH Labor. All samples have been collected from form patients hospitalized in April 2020. Sera in the control group tested negative for COVID-19 infection in the EUROIMMUN IgG Elisa Test. We used samples from different specialties, including cardiology, gastroenterology, nephrology and the intensive care unit.

SARS-CoV-2 infected group: COVID-19 patients (n=13 female, age range 23 to 70 years; n=11 male, age range 35 to 70 years) were recruited across the spectrum of clinical severity, ranging from asymptomatic/mild to severe/SARS. COVID-19 diagnosis was confirmed either by diagnostic PCR and/or commercial ELISA carried out 14 days or later after the onset of symptoms. Detailed information on all patients and samples is provided in **Supplementary Table 3.**

Inclusion/exclusion criteria were: Fully conversant in the German or English language, able and willing to attend to the study requirements, written informed consent to participate in

376 this study / history of four or more infections with antibiotic treatment in the last year, se-
377 vere liver or kidney disease, patients with immunotherapy, patients that suffer from any on-
378 cological disease.

379 To ensure valid test results we screened patients according to the specified inclusion and
380 exclusion criteria. All Patients were interviewed systematically according to an anamnestic
381 questionnaire. To validate COVID-19 cases, RT-PCR, clinical diagnosis and the result of
382 the Euroimmune IgG Assay were used in conjunction. Patients were questioned about the
383 time of onset of symptoms. All Patients included in this study could precisely specify at
384 which date symptoms occurred. After the onset of symptoms, all but one Patient under-
385 went RT-PCR testing and tested positive for COVID-19. We ensured that no patient took
386 medicine or suffered from a disease that could potentially affect the development of anti-
387 bodies. The severity of COVID-19 was determined on the basis of WHO guidelines into
388 asymptomatic, mild (common cold-like symptoms), moderate (dyspnea, clinical signs of
389 pulmonary distress) and severe (requiring oxygen supplementation, intensive care with or
390 without ventilation) [WHO Global, 2020].

391
392 **Peptide microarrays.** Antibody response profiling was performed with a peptide microar-
393 ray (JPT Peptide Technologies GmbH) containing 5513 peptides covering the full pro-
394 teome of SARS-CoV-2 and, in addition, the S, N, E, and M proteins of the following
395 HCoV-1: SARS-CoV-1, MERS-CoV, HCoV 229E, OC43. All proteins were represented by
396 overlapping peptides covering the entire protein sequence (15 aa length, 11 aa overlap).
397 All proteins covered by the peptide library are listed in **Supplementary Table 1**.

398
399 **Peptide synthesis and microarray production.** Peptides were synthesized and immobi-
400 lized on peptide microarray slides as described previously [Stephenson et al., 2015]. In
401 brief, the peptides were synthesized using SPOT synthesis [Wenschuh et al., 2000],
402 cleaved from the solid support and chemoselectively immobilized on functionalized glass
403 slides. Each peptide was deposited on the microarray in triplicates.

404
405 **Microarray assay and data analysis.** The peptide microarrays were incubated with sera
406 (applied dilution 1:200) in an HS 4800 microarray processing station (Tecan) for two hours
407 at 30°C, followed by incubation with 0.1 µg/mL fluorescently labelled anti human IgG de-
408 tection antibody (Jackson ImmunoResearch, 109-605-098). Washing steps were performed
409 prior to every incubation step with 0.1% Tween-20 in 1x TBS. After the final incubation

step the microarrays were washed (0.05% Tween-20 in 0.1x SSC) and dried in a stream of nitrogen. Each microarray was scanned using a GenePix Autoloader 4300 SL50 (Molecular Devices, Pixel size: 10 μ m). Signal intensities were evaluated using GenePix Pro 7.0 analysis software (Molecular Devices). For each peptide, the MMC2 value of the three triplicates was calculated. The MMC2 value was equal to the mean value of all three instances on the microarray except when the coefficient of variation (CV) – standard-deviation divided by the mean value – was larger than 0.5. In this case the mean of the two values closest to each other (MC2) was assigned to MMC2. Further data analysis and generation of the heatmaps was performed using the statistical computing and graphics software R (Version 4.0.2, www.r-project.org).

RT-PCR test.

We used the protocol described by the centers for disease control and prevention for the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)–PCR Diagnostic Panel.

ELISA test. To detect antibodies, we used the Euroimmun Anti-SARS-CoV-2 ELISA (IgG), which was manufactured by Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany. The break-off microplate wells were covered with the antigen, a recombinant structural spike 1 (S1) protein of SARS-CoV-2 expressed in HEK293 [FDA, 2020]. First, the diluted patient samples were incubated in the wells which lead to specific IgG antibodies binding to the antigens. In order to detect the bound antibodies, an enzyme-labelled anti-human IgG antibody detected antigen-antibody complexes and catalysed a colour reaction. By calculating the extinction of the sample over the extinction of the calibrator the results could be evaluated semi-quantitatively. A ratio below 0.8 was considered a negative result. A ratio between 0.8 and 1.1 was considered a borderline result. A ratio above 1.1 was considered a positive result [Euroimmun Medizinische Labordiagnostika AG, 2020].

QUANTIFICATION AND STATISTICAL ANALYSIS

Data analysis and heatmap generation was performed using the statistical computing and graphics software R (Version 4.0.2, www.r-project.org).

The data set used for statistical analysis of the microarray results and for generation of all heatmap presentations was based on MMC2 values calculated from signals of the triplicate spots of each individual peptide. The MMC2 value calculation is described in detail in the *Microarray assay and data analysis* section.

445 The principle of the colour coding of all heatmaps is described in the corresponding figure
446 legends. The coloured fields in the heatmaps reflect the calculated MMC2 values of each
447 individual peptide.

448 The boxplots in **Figure 1** and **Figure 2** show the median of the corresponding sample
449 groups. The central rectangles span the first quartile to the third quartile (the *interquartile*
450 *range* or *IQR*). The whiskers represent the following values: upper whisker = $\min(\max(x),$
451 $\text{Quartile } 3 + 1.5 * \text{IQR})$; lower whisker = $\max(\min(x), \text{Quartile } 1 - 1.5 * \text{IQR})$. The points in
452 the boxplots show the MMC2 values for the individual samples.

453 Statistical comparison of two sample groups was done by the Wilcoxon Rank Sum test (R
454 package *stats*, n=24 patient samples and n=12 control samples). ROC analysis was per-
455 formed using the R package *ROCR*. The selection of the peptide hits with significant
456 separation between the sample groups was based on the accuracy value calculated as
457 '(true positive + true negative)/total number of observations'. An accuracy value of ≥ 0.4
458 was considered to indicate immunogenicity (**Supplementary Table 2**). Immunodominance
459 was assigned to epitopes based on the highest accuracy scores and the sequences of the
460 corresponding overlapping peptides (**Table 1**).

461 The Spearman's rank correlation coefficient reflecting the relationship between the com-
462 mercial ELISA and the peptide microarray (**Figure 3**) was calculated as described in the
463 figure legend using the R package *ggpubr*.

464

465 References

- 466 Abdelmageed, M. I., Abdelmoneim, A. H., Mustafa, M. I., Elfadol, N. M., Murshed, N. S., Shantier,
467 S. W., & Makhawi, A. M. (2020). Design of a Multiepitope-Based Peptide Vaccine against the E
468 Protein of Human COVID-19: An Immunoinformatics Approach. *BioMed research interna-*
469 *tional*, 2020, 2683286. <https://doi.org/10.1155/2020/2683286>.
- 470 Amrun, S. N., Lee, C. Y., Lee, B., Fong, S. W., Young, B. E., Chee, R. S., Yeo, N. K., Torres-
471 Ruesta, A., Carissimo, G., Poh, C. M., Chang, Z. W., Tay, M. Z., Chan, Y. H., Chen, M. I., Low, J.
472 G., Tambyah, P. A., Kalimuddin, S., Pada, S., Tan, S. Y., Sun, L. J., ... Ng, L. (2020). Linear B-cell
473 epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease
474 severity. *EBioMedicine*, 58, 102911. Advance online publication. <https://doi.org/10.1016/j.ebiom.2020.102911>.
- 476 Andresen, H., Zarse, K., Grötzinger, C., Hollidt, J. M., Ehrentreich-Förster, E., Bier, F. F., & Kreu-
477 zer, O. J. (2006). Development of peptide microarrays for epitope mapping of antibodies against
478 the human TSH receptor. *Journal of immunological methods*, 315(1-2), 11–18. <https://doi.org/10.1016/j.jim.2006.06.012>.
- 480 Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavec-
481 chia, A., Corti, D., & Virgin, H. W. (2020). A perspective on potential antibody-dependent enhance-
482 ment of SARS-CoV-2. *Nature*, 584(7821), 353–363. <https://doi.org/10.1038/s41586-020-2538-8>.
- 483 Baraniak I, Kern F, Holenya P, Griffiths P, Reeves M. (2019). Original Antigenic Sin Shapes the
484 Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in
485 Seropositive Recipients. *J. Infect. Dis.* 220(2), 228-232. doi:10.1093/infdis/jiz089.
- 486 Bond, K., Nicholson, S., Lim, S. M., Karapanagiotidis, T., Williams, E., Johnson, D., Hoang, T., Sia,
487 C., Purcell, D., Mordant, F., Lewin, S. R., Catton, M., Subbarao, K., Howden, B. P., & Williamson,
488 D. A. (2020). Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a
489 low-prevalence setting. *The Journal of infectious diseases*, jiaa467. Advance online publication.
490 <https://doi.org/10.1093/infdis/jiaa467>.
- 491 Bonifacius, A., et al. (2020). COVID-19 immune signatures reveal stable antiviral T-cell function de-
492 spite declining humoral responses. *Immunity*. Sneak Peek, Available at SSRN: [https://ssrn.com/ab-](https://ssrn.com/abstract=3661946)
493 [stract=3661946 or http://dx.doi.org/10.2139/ssrn.3661946](http://dx.doi.org/10.2139/ssrn.3661946)
- 494 Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey,
495 M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K.,
496 Röhm, J., Voigt, S., Schmitz, J., Miltenyi, S., ... Thiel, A. (2020). SARS-CoV-2-reactive T cells in
497 healthy donors and patients with COVID-19. *Nature*, 10.1038/s41586-020-2598-9. Advance online
498 publication. <https://doi.org/10.1038/s41586-020-2598-9>.
- 499 Dahlke, C., Heidepriem, J., Kobbe, R., Santer, R., Koch, T., Fathi, A., Ly, L., Schmiedel, S., See-
500 berger, P., Addo, M., Loeffler, F. (2020). Distinct early IgA profile may determine severity of
501 COVID-19 symptoms: an immunological case series. medRxiv 2020.04.14.20059733, [https://](https://doi.org/10.1101/2020.04.14.20059733)
502 doi.org/10.1101/2020.04.14.20059733.
- 503 Euroimmun Medizinische Labordiagnostika AG (2020), Characteristics of EUROIMMUN ELISA for
504 COVID-19 diagnostics. available at: [https://www.coronavirus-diagnostics.com/antibody-detection-](https://www.coronavirus-diagnostics.com/antibody-detection-tests-for-covid-19)
505 [tests-for-covid-19](https://www.coronavirus-diagnostics.com/antibody-detection-tests-for-covid-19).
- 506 Farrera, L., Daguer, J.-P., Barluenga, S., Cohen, P., Pagano, S., Yerly, S., Kaiser, L., Vuilleumier,
507 N., Winssinger N. (2020). Identification of immunodominant linear epitopes from SARS-CoV-2 pa-
508 tient plasma. *PloS one*, 15(9), e0238089. <https://doi.org/10.1371/journal.pone.0238089>.
- 509 FDA (Food and Drug Administration) (2020). Anti-SARS-CoV-2 ELISA (IgG). Instruction for use.
510 Available at: <https://www.fda.gov/media/137609/download>.
- 511 Grifoni, A., Sidney, J., Zhang, Y., Scheuermann, R. H., Peters, B., & Sette, A. (2020). A Sequence
512 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to
513 SARS-CoV-2. *Cell host & microbe*, 27(4), 671–680.e2. <https://doi.org/10.1016/j.chom.2020.03.002>.

- 514 Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Huon, C., Guivel, F., Staropoli, I., Chazal,
515 M., Dufloo, J., Planas, D. et al. (2020). SARS-CoV-2 serological analysis of COVID-19 hospitalized
516 patients, pauci-symptomatic individuals and blood donors. *medRxiv* 2020.04.21.20068858, <https://doi.org/10.1101/2020.04.21.20068858>.
517
- 518 Guo, J. P., Petric, M., Campbell, W., & McGeer, P. L. (2004). SARS corona virus peptides recog-
519 nized by antibodies in the sera of convalescent cases. *Virology*, 324(2), 251–256. <https://doi.org/10.1016/j.virol.2004.04.017>.
520
- 521 Huang, A. T., Garcia-Carreras, B., Hitchings, M., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borg-
522 ert, B. A., Moreno, C. A., Solomon, B. D., Rodriguez-Barraquer, I., Lessler, J., Salje, H., Burke, D.,
523 Wesolowski, A., & Cummings, D. (2020). A systematic review of antibody mediated immunity to
524 coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses
525 with severity of disease. *Nature communications*, 11(1), 4704. [https://doi.org/10.1038/s41467-020-](https://doi.org/10.1038/s41467-020-18450-4)
526 18450-4.
- 527 Krammer, F., & Simon, V. (2020). Serology assays to manage COVID-19. *Science (New York,*
528 *N.Y.)*, 368(6495), 1060–1061. <https://doi.org/10.1126/science.abc1227>.
- 529 Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L. P., Johnston, J. C., Lan,
530 Z., Law, S., MacLean, E., Trajman, A., Menzies, D., Benedetti, A., & Ahmad Khan, F. (2020). Diag-
531 nostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ (Clini-*
532 *cal research ed.)*, 370, m2516. <https://doi.org/10.1136/bmj.m2516>.
- 533 Liu, T., Wu, S., Zeng, G., Zhou, F., Li, Y., Guo, F., & Wang, X. (2020). Recurrent positive SARS-
534 CoV-2: Immune certificate may not be valid. *Journal of medical virology*, 10.1002/jmv.26074. Ad-
535 vance online publication. <https://doi.org/10.1002/jmv.26074>.
- 536 Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y.,
537 Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang,
538 X. L., Tian, W. G., ... Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with
539 COVID-19. *Nature medicine*, 26(6), 845–848. <https://doi.org/10.1038/s41591-020-0897-1>.
- 540 Lv et al., (2020). Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infec-
541 tions. *Cell Reports* 31, 107725.
- 542 NIH 2020, Management of Persons with COVID-19.
543 <https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/>.
- 544 Poh, C. M., Carissimo, G., Wang, B., Amrun, S. N., Lee, C. Y., Chee, R. S., Fong, S. W., Yeo, N.
545 K., Lee, W. H., Torres-Ruesta, A., Leo, Y. S., Chen, M. I., Tan, S. Y., Chai, L., Kalimuddin, S.,
546 Kheng, S., Thien, S. Y., Young, B. E., Lye, D. C., Hanson, B. J., ... Ng, L. (2020). Two linear epi-
547 topes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 pa-
548 tients. *Nature communications*, 11(1), 2806. <https://doi.org/10.1038/s41467-020-16638-2>.
- 549 Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M.,
550 Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., Molina, M., Rodríguez-
551 Cabrera, F., Martín, M., Merino-Amador, P., León Paniagua, J., Muñoz-Montalvo, J. F., Blanco, F.,
552 Yotti, R., & ENE-COVID Study Group (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID):
553 a nationwide, population-based seroepidemiological study. *Lancet (London, England)*, S0140-
554 6736(20)31483-5. Advance online publication. [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5).
- 555 Shichijo, S., Keicho, N., Long, H. T., Quy, T., Phi, N. C., Ha, L. D., Ban, V. V., Itoyama, S., Hu, C.
556 J., Komatsu, N., Kirikae, T., Kirikae, F., Shirasawa, S., Kaji, M., Fukuda, T., Sata, M., Kuratsuji, T.,
557 Itoh, K., & Sasazuki, T. (2004). Assessment of synthetic peptides of severe acute respiratory syn-
558 drome coronavirus recognized by long-lasting immunity. *Tissue antigens*, 64(5), 600–607. <https://doi.org/10.1111/j.1399-0039.2004.00314.x>.
559
- 560 Siracusano, G., Pastori, C., & Lopalco, L. (2020). Humoral Immune Responses in COVID-19 Pa-
561 tients: A Window on the State of the Art. *Frontiers in immunology*, 11, 1049. <https://doi.org/10.3389/fimmu.2020.01049>.
562
- 563 Smith, C. C., Entwistle, S., Willis, C., Vensko, S., Beck, W., Garness, J., Sambade, M., Routh, E.,
564 Olsen, K., Kodysh, J., O'Donnell, T., Haber, C., Heiss, K., Stadler, V., Garrison, E., Grant, O. C.,
39
40

565 Woods, R. J., Heise, M., Vincent, B. G., & Rubinsteyn, A. (2020). Landscape and Selection of Vac-
566 cine Epitopes in SARS-CoV-2. *bioRxiv* 2020.06.04.135004, [https://doi.org/](https://doi.org/10.1101/2020.06.04.135004)
567 10.1101/2020.06.04.135004.

568 Stephenson, K. E., Neubauer, G. H., Reimer, U., Pawlowski, N., Knaute, T., Zerweck, J., Korber,
569 B. T., & Barouch, D. H. (2015). Quantification of the epitope diversity of HIV-1-specific binding anti-
570 bodies by peptide microarrays for global HIV-1 vaccine development. *Journal of immunological*
571 *methods*, 416, 105–123. <https://doi.org/10.1016/j.jim.2014.11.006>.

572 Tilocca, B., Soggiu, A., Sanguinetti, M., Musella, V., Britti, D., Bonizzi, L., Urbani, A., & Roncada,
573 P. (2020). Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in
574 taxonomically related coronaviruses. *Microbes and infection*, 22(4-5), 188–194. [https://doi.org/](https://doi.org/10.1016/j.micinf.2020.04.002)
575 10.1016/j.micinf.2020.04.002.

576 Wang, H., Hou, X., Wu, X., Liang, T., Zhang, X., Wang, D., Teng, F., Dai, J., Duan, H., Guo, S., Li,
577 Y., Yu, X. (2020) SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions
578 at amino acid resolution. *ACS Cent. Sci.* <https://doi.org/10.1021/acscentsci.0c00742>.

579 WHO (2020). Coronavirus disease (COVID-2019) situation reports. Available at: [https://](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)
580 www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

581 WHO Global (2020). Clinical Management Of COVID-19. Available at: [https://www.who.int/publica-](https://www.who.int/publications/i/item/clinical-management-of-covid-19)
582 [tions/i/item/clinical-management-of-covid-19](https://www.who.int/publications/i/item/clinical-management-of-covid-19).

583 Zhang1, B. Z., Hu, Y. F., Chen, L. L., Yau, T., Tong, Y. G., Hu, J. C., Cai, J. P., Chan, K. H., Dou,
584 Y., Deng, J., Wang, X. L., Hung, I. F., To, K. K., Yuen, K. Y., & Huang, J. D. (2020). Mining of epi-
585 topes on spike protein of SARS-CoV-2 from COVID-19 patients. *Cell research*, 30(8), 702–704.
586 <https://doi.org/10.1038/s41422-020-0366-x>

587 Zhang2, B., Hu, Y., Chen, L., Tong, Y., Hu, J., Cai, J., Chan, K.-H., Dou, Y., Deng, J., Gong, H. et
588 al. (2020). Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the De-
589 sign of Vaccines against COVID-19. *bioRxiv* 2020.04.23.056853, [https://doi.org/](https://doi.org/10.1101/2020.04.23.056853)
590 10.1101/2020.04.23.056853.

591

592

593

Nucleoprotein

Supplementary Figure 1. Peptide microarray analysis of IgG responses to Nucleoprotein (N) of different coronaviruses. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

Supplementary Figure 2. Peptide microarray analysis of IgG responses to Spike glycoprotein (S) of different coronaviruses. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

621

Membrane protein

622

623

624

625

626

627

628

629

630

631

632

633

634

Supplementary Figure 3. Peptide microarray analysis of IgG responses to Membrane protein (M) of different coronaviruses. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

635

Envelope small membrane protein

636

637

638

639

640

641

642

643

644

645

Supplementary Figure 4. Peptide microarray analysis of IgG responses to envelope small membrane protein (E) of different coronaviruses. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

SARS-CoV-2 non-structural proteins processed from Replicase polyprotein 1ab

Supplementary Figure 5. Peptide microarray analysis of IgG responses to SARS-CoV-2 non-structural proteins processed from Replicase polyprotein 1ab. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

Other SARS-CoV-2 proteins

Supplementary Figure 6. Peptide microarray analysis of IgG responses to other non-structural proteins of SARS-CoV-2. Heatmaps represent two groups of serum samples: SARS-CoV-2 infected and control groups. The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). Columns represent peptide sequences, rows represent samples. Colours indicate the signal values obtained from triplicate spots ranging from white (0 or low intensity) over yellow (middle intensity) to red (maximal intensity of 65535 light units). The two left rows of the heatmaps reflect signals obtained with detection antibody only (no serum). The upper row in each heatmap reflects the highest possible signal intensity.

Supplementary Table 1: Proteins examined in the study.*

UniProtKB entry name	Number of peptides	Protein	Organism
A0A663DJA2_9BETC	7	ORF10 protein	SARS-CoV-2
AP3A_WCPV	66	Protein 3a	SARS-CoV-2
NCAP_WCPV	102	Nucleoprotein	SARS-CoV-2
NS6_WCPV	13	Non-structural protein 6	SARS-CoV-2
NS7A_WCPV	28	Protein 7a	SARS-CoV-2
NS7B_WCPV	8	Protein non-structural 7b	SARS-CoV-2
NS8_WCPV	28	Non-structural protein 8	SARS-CoV-2
ORF9B_WCPV	22	Protein 9b	SARS-CoV-2
R1A_WCPV	1099	Replicase polyprotein 1a	SARS-CoV-2
R1AB_WCPV	1772	Replicase polyprotein 1ab	SARS-CoV-2
SPIKE_WCPV	316	Spike glycoprotein	SARS-CoV-2
VEMP_WCPV	16	Envelope small membrane protein	SARS-CoV-2
VME1_WCPV	53	Membrane protein	SARS-CoV-2
Y14_WCPV	16	Uncharacterized protein 14	SARS-CoV-2
NCAP_CVHSA	103	Nucleoprotein	SARS-CoV
SPIKE_CVHSA	311	Spike glycoprotein	SARS-CoV
VEMP_CVHSA	17	Envelope small membrane protein	SARS-CoV
VME1_CVHSA	53	Membrane protein	SARS-CoV
NCAP_CVHOC	110	Nucleoprotein	OC43
SPIKE_CVHOC	336	Spike glycoprotein	OC43
VEMP_CVHOC	19	Envelope small membrane protein	OC43
VME1_CVHOC	55	Membrane protein	OC43
NCAP_CVEMC	100	Nucleoprotein	MERS
SPIKE_CVEMC	336	Spike glycoprotein	MERS
VEMP_CVEMC	18	Envelope small membrane protein	MERS
VME1_CVEMC	52	Membrane protein	MERS
NCAP_CVH22	95	Nucleoprotein	229E
SPIKE_CVH22	291	Spike glycoprotein	229E
VEMP_CVH22	17	Envelope small membrane protein	229E
VME1_CVH22	54	Membrane protein	229E

*: The mnemonic organism identification code of SARS-CoV-2 has been changed. In the updated version, all UniProtKB entry names of SARS-CoV-2 contain the "_SARS2" species identification code instead of "_WCPV".

Supplementary Table 2: Statistical analysis of all data to identify immunodominant epitopes. The peptides are ranked according to the calculated accuracy value which equals the ratio of the sum of all true positive and true negative cases to the total number of instances. An accuracy of 0.4 is set as a cut-off value for delimitation of the sufficient immunogenicity. 81 Peptides were identified.
See appended Excel list.

683 **Supplementary Table 3: Patient demographics.**

684 See appended Excel list.

685

686

687

688 **Figure 1.**

689

690

691

692

693 **Figure 2.**

694
695
696
697
698

699 **Figure 3.**

700

701

702

703

704 **Figure 4.**

705

706

707

708

Figure 5.